{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tan AR"],"funding":["UPCI Cancer Pharmacokinetics and Pharmacodynamics Facility","National Cancer Institute","NCI NIH HHS"],"pagination":["49-58"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8934569"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["89(1)"],"pubmed_abstract":["<h4>Purpose</h4>Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus iv doxorubicin (A) and C.<h4>Methods</h4>Objectives were to establish the maximum tolerated dose (MTD) of the combinations, characterize V pharmacokinetics (PK) in the presence and absence of C, measure PAR in peripheral blood mononuclear cells (PBMCs) and γH2AX in circulating tumor cells (CTCs). In Group 1, dose escalations of V from 10 to 50 mg every 12 h Days 1-4 plus C 450 to 750 mg/m<sup>2</sup> Day 3 in 21-day cycles were evaluated. In Group 2, V doses ranged from 50 to 150 mg every 12 h Days 1-4 with AC (60/600 mg/m<sup>2</sup>) "],"journal":["Cancer chemotherapy and pharmacology"],"pubmed_title":["A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies."],"pmcid":["PMC8934569"],"funding_grant_id":["UM1-CA-186690","R50CA211241","UM1 CA186716","U01-CA099168","U01 CA132194","U24 CA247643","U01 CA099168","UM1-CA-186716","P30 CA047904","UM1 CA186690","U01-CA-132194-01","P30-CA47904","R50 CA211241"],"pubmed_authors":["Shah M","Gounder M","Malhotra J","Kane MP","Mehnert JM","Kiesel BF","Lin Y","Ji J","Beumer JH","Aisner J","Tan AR","Stein MN","Chen A","Lin H","Chan N","Moss RA"],"additional_accession":[]},"is_claimable":false,"name":"A phase I study of veliparib with cyclophosphamide and veliparib combined with doxorubicin and cyclophosphamide in advanced malignancies.","description":"<h4>Purpose</h4>Veliparib (V), an oral poly(ADP-ribose) polymerase (PARP) inhibitor, potentiates effects of alkylating agents and topoisomerase inhibitors in preclinical tumor models. We conducted a phase I trial of V with iv cyclophosphamide (C) and V plus iv doxorubicin (A) and C.<h4>Methods</h4>Objectives were to establish the maximum tolerated dose (MTD) of the combinations, characterize V pharmacokinetics (PK) in the presence and absence of C, measure PAR in peripheral blood mononuclear cells (PBMCs) and γH2AX in circulating tumor cells (CTCs). In Group 1, dose escalations of V from 10 to 50 mg every 12 h Days 1-4 plus C 450 to 750 mg/m<sup>2</sup> Day 3 in 21-day cycles were evaluated. In Group 2, V doses ranged from 50 to 150 mg every 12 h Days 1-4 with AC (60/600 mg/m<sup>2</sup>) ","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Jan","modification":"2025-04-19T18:08:13.337Z","creation":"2025-04-19T18:08:13.337Z"},"accession":"S-EPMC8934569","cross_references":{"pubmed":["34669023"],"doi":["10.1007/s00280-021-04350-x"]}}